Skip to main content

Advertisement

SpringerLink
Log in

Inflammation

Rituximab in ANCA vasculitis and lupus: bittersweet results

  • News & Views
  • Published:

From Nature Reviews Nephrology

View current issue Sign up to alerts

Recent randomized, controlled trials suggest that B-cell-depletion therapy with rituximab effectively induces remission in anti-neutrophil-cytoplasmic-antibody-associated vasculitis but is ineffective in patients with lupus nephritis or nonrenal systemic lupus erythematosus with moderate-to-severe disease activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Furie, R. et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum. [online], (2009).

  2. Furie, R. et al. Effect of rituximab (RTX) on anti-dsDNA and C3 levels and relationship to response: results from the LUNAR trial. Arthritis Rheum. [online], (2009).

  3. Merrill, J. T. et al. Flare assessment in systemic lupus erythematosus (SLE) patients treated with rituximab in the phase II/III EXPLORER trial. Arthritis Rheum. [online], (2009).

  4. Merrill, J. T. et al. Treatment of systemic lupus erythematosus (SLE) with rituximab: 78-week safety data from the phase II/II EXPLORER trial. Arthritis Rheum. [online], (2009).

  5. Stone, J. H. et al. Rituximab versus cyclophosphamide for induction of remission in ANCA-associated vasculitis: a randomized controlled trial (RAVE). Arthritis Rheum. [online], (2009).

  6. Bosch, X., Guilabert, A., Espinosa, G. & Mirapeix, E. Immunotherapy for antineutrophil cytoplasmic antibody-associated vasculitis: challenging the therapeutic status quo? Trends Immunol. 29, 280–289 (2008).

    Article  CAS  Google Scholar 

  7. Walsh, M. & Jayne, D. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney Int. 72, 676–682 (2007).

    Article  CAS  Google Scholar 

  8. Ng, K. P. et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann. Rheum. Dis. 66, 1259–1262 (2007).

    Article  CAS  Google Scholar 

  9. Favas, C. & Isenberg, D. A. B-cell-depletion therapy in SLE—what are the current prospects for its acceptance? Nat. Rev. Rheumatol. 5, 711–716 (2009).

    Article  CAS  Google Scholar 

  10. John Looney, R., Anolik, J. & Sanz, I. A perspective on B-cell-targeting therapy for SLE. Mod. Rheumatol. doi: 10.1007/s10165-009-0213-x.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Hospital Clínic, Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Villarroel 170, 08036, Barcelona, Spain

    Xavier Bosch

Authors
  1. Xavier Bosch
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bosch, X. Rituximab in ANCA vasculitis and lupus: bittersweet results. Nat Rev Nephrol 6, 137–139 (2010). https://doi.org/10.1038/nrneph.2010.13

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2010.13

  • Springer Nature Limited

This article is cited by

Search

Navigation